Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;70(2):297-308.
doi: 10.1136/gutjnl-2020-320945. Epub 2020 May 30.

Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden

Affiliations

Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden

Jordan E Axelrad et al. Gut. 2021 Feb.

Abstract

Objective: Crohn's disease (CD) is associated with increased risk of small bowel cancer (SBC), but previous studies have been small. We aimed to examine the risk of incident SBC and death from SBC in patients with inflammatory bowel disease (IBD).

Design: In a binational, population-based cohort study from Sweden and Denmark of patients with IBD during 1969-2017 and matched reference individuals from the general population, we evaluated the risk of incident SBC and death from SBC. Cox regression was used to estimate adjusted hazard ratios (aHRs).

Results: We identified 161 896 individuals with IBD (CD: 47 370; UC: 97 515; unclassified IBD: 17 011). During follow-up, 237 cases of SBC were diagnosed in patients with IBD (CD: 24.4/100 000 person-years; UC: 5.88/100 000 person-years), compared with 640 cases in reference individuals (2.81/100 000 person-years and 3.32/100 000 person-years, respectively). This corresponded to one extra case of SBC in 385 patients with CD and one extra case in 500 patients with UC, followed up for 10 years. The aHR for incident SBC was 9.09 (95% CI 7.34 to 11.3) in CD and 1.85 (95% CI 1.43 to 2.39) in UC. Excluding the first year after an IBD diagnosis, the aHRs for incident SBC decreased to 4.96 in CD and 1.69 in UC. Among patients with CD, HRs were independently highest for recently diagnosed, childhood-onset, ileal and stricturing CD. The relative hazard of SBC-related death was increased in both patients with CD (aHR 6.59, 95% CI 4.74 to 9.15) and patients with UC (aHR 1.57; 95% CI 1.07 to 2.32).

Conclusion: SBC and death from SBC were more common in patients with IBD, particularly among patients with CD, although absolute risks were low.

Keywords: Crohn's disease; adenocarcinoma; cancer; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JA has served as a consultant for Aetion and BioFire diagnostics. OO has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen and Ferring. He also reports a grant from Pfizer in the context of a national safety monitoring programme. None of those studies has any relation to the present study. The Karolinska Institutet has received fees for Olén’s lectures and participation on advisory boards from Janssen, Ferring, Takeda and Pfizer regarding topics not related to the present study. JA acts or has acted as PI for agreements between Karolinska Institutet and grants from AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB, mainly in the context of a national safety monitoring programme for immunomoduators in rheumatology (ARTIS). JLF coordinates a study unrelated to the present study on behalf of the Swedish IBD Quality Register (SWIBREG). That study has received funding from Janssen. JH has served as speaker and/or advisory board member for AbbVie, Celgene, Celltrion, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Tillotts Pharma, Vifor Pharma and UCB. He also has received grant support from Janssen, MSD and Takeda. The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies has any relation to the present study.

Comment in

Similar articles

Cited by

Publication types

LinkOut - more resources